Infinity Pharma

Overcoming barriers, pushing boundaries and bringing the latest to the masterful market is the goal of Infinity Pharma®. A brand that has in its DNA the innovative spirit and evolution as fundamental pieces, capable of transforming the segment leading brand, reference in prevention and innovation of individualized treatment, into a business model with an identity that represents a new vision for the future with infinite possibilities. Inspired by infinity, the company begins a new cycle and aims to exceed the expectations of master consumers, doctors and pharmacists, combining quality, research and technology in new proposals for individualization, with unique assets. With brand-leading experience, Infinity Pharma® has established itself as a company specializing in individualized treatment, reference in prevention and innovation in products, services and concepts for health professionals and the master market.

Related News

FILING BUZZER: LEARN WHY BIOTECHNOLOGY VALUE FUND L P JUST PURCHASED INFINITY PHARMACEUTICALS, INC STAKE?

Pharamaceutical | December 30, 2016

news image

Biotechnology Value Fund L P filed with the SEC SC 13G/A form for Infinity Pharmaceuticals, Inc. The form can be accessed here: 000092189516006421. As reported in Biotechnology Value Fund L P’s form, the filler as of late owns 15.8% or 7,860,808 shares of the Health Care–company....

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

POLL: UTAH VOTERS BACK CAP ON CO-PAYS FOR INSULIN PRESCRIPTIONS

Public News Service | January 14, 2020

news image

The skyrocketing cost of prescription drugs has become a bipartisan issue among voters, and Utahns overwhelmingly back a plan to help diabetics overcome the cost of life-saving insulin. A new poll from UtahPolicy.com Y-2 Analytics finds 4 out of 5 registered voters would support legislation to cap out-of-pocket costs for insulin. The idea mirrors a bill passed in Colorado in 2019 to limit a patient's out-of-pocket costs for insulin, a hormone critical to diabetics for controlling their blood...

Read More

ROCHE AND ILLUMINA FORGE GENOMICS ALLIANCE FOR CANCER TESTING

pharma news | January 14, 2020

news image

Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS player – Pacific Biosciences or PacBio – after concluding it would be unlikely to make it past antitrust regulators in the US and UK. Illumina is thought to have around 80% of the DNA sequ...

Read More
news image

FILING BUZZER: LEARN WHY BIOTECHNOLOGY VALUE FUND L P JUST PURCHASED INFINITY PHARMACEUTICALS, INC STAKE?

Pharamaceutical | December 30, 2016

Biotechnology Value Fund L P filed with the SEC SC 13G/A form for Infinity Pharmaceuticals, Inc. The form can be accessed here: 000092189516006421. As reported in Biotechnology Value Fund L P’s form, the filler as of late owns 15.8% or 7,860,808 shares of the Health Care–company....

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

POLL: UTAH VOTERS BACK CAP ON CO-PAYS FOR INSULIN PRESCRIPTIONS

Public News Service | January 14, 2020

The skyrocketing cost of prescription drugs has become a bipartisan issue among voters, and Utahns overwhelmingly back a plan to help diabetics overcome the cost of life-saving insulin. A new poll from UtahPolicy.com Y-2 Analytics finds 4 out of 5 registered voters would support legislation to cap out-of-pocket costs for insulin. The idea mirrors a bill passed in Colorado in 2019 to limit a patient's out-of-pocket costs for insulin, a hormone critical to diabetics for controlling their blood...

Read More
news image

ROCHE AND ILLUMINA FORGE GENOMICS ALLIANCE FOR CANCER TESTING

pharma news | January 14, 2020

Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS player – Pacific Biosciences or PacBio – after concluding it would be unlikely to make it past antitrust regulators in the US and UK. Illumina is thought to have around 80% of the DNA sequ...

Read More